Sophie Tartas

Oullins, FR 
Clinical Trials:Currently Recruiting for 2 Trials
Oullins, FR 
OverviewLocationsClinical Research

Overview

Sophie Tartas practices in Oullins, France. Her top areas of expertise are Persistent Mullerian Duct Syndrome, Renal Cell Carcinoma (RCC), Prostate Cancer, and Urothelial Cancer.

Her clinical research consists of co-authoring 24 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Oullins, France
Other Locations
Hospices Civils de Lyon, Oullins Pierre Bénite
Lyon, France
Pierre-la-treiche, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy
Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy
Enrollment Status: Recruiting
Publish Date: October 16, 2024
Intervention Type: Behavioral
Study Phase: Not Applicable
Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Enrollment Status: Recruiting
Publish Date: March 04, 2024
Intervention Type: Genetic
Study Phase: Not Applicable
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Enrollment Status: Unknown
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drugs: AZD2014, Anastrozole
Study Phase: Phase 1/Phase 2
iDEFCO: Implementation of a Tool to Identify Social Weaknesses in the Cancer Care Pathway
iDEFCO: Implementation of a Tool to Identify Social Weaknesses in the Cancer Care Pathway
Enrollment Status: Terminated
Publish Date: November 02, 2023
Intervention Type: Other
A Phase I Dose Escalation Trial Evaluating the Impact of an in Situ Immunization Strategy With Intra-Tumoral Injections of Pexa-Vec in Combination With Ipilimumab in Metastatic / Advanced Solid Tumors With Injectable Lesions.
A Phase I Dose Escalation Trial Evaluating the Impact of an in Situ Immunization Strategy With Intra-Tumoral Injections of Pexa-Vec in Combination With Ipilimumab in Metastatic / Advanced Solid Tumors With Injectable Lesions.
Enrollment Status: Completed
Publish Date: July 25, 2022
Intervention Type: Drug, Biological
Study Phase: Phase 1
A Phase II, Multicenter Trial Aiming to Evaluate the Clinical Interest of a Monotherapy With BKM120 , a Phosphoinositide 3-kinase (PI3K) Inhibitor in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive Under Platin and Cetuximab-based Chemotherapy
A Phase II, Multicenter Trial Aiming to Evaluate the Clinical Interest of a Monotherapy With BKM120 , a Phosphoinositide 3-kinase (PI3K) Inhibitor in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive Under Platin and Cetuximab-based Chemotherapy
Enrollment Status: Completed
Publish Date: June 24, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

24 Total Publications

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Tartas's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile